Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

16  Enrolling
17  Total Trials
Pinned
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
Enrolling
Conditions: Migraine
Trial Name
PIONEER-PEDS1
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
Pinned
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)
Enrolling
Conditions: Migraine
Trial Name
REBUILD-1
Drugs: Galcanezumab
Age
6 - 17 years
Phase
III
Pinned
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)
Enrolling
Conditions: Migraine
Trial Name
REBUILD-2
Drugs: Galcanezumab
Age
12 - 17 years
Phase
III
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma (CAMPFIRE)
Enrolling
Conditions: Ewing's Sarcoma
Trial Name
CAMPFIRE
Drugs: Abemaciclib (LY2835219)
Age
1 year - 39 years
Phase
II
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Enrolling
Conditions: Systemic Juvenile Idiopathic Arthritis
Drugs: Baricitinib
Age
1 year - 17 years
Phase
III
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)
Enrolling
Conditions: Migraine
Trial Name
PIONEER-PEDS2
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)
Enrolling
Conditions: COVID-19
Trial Name
COV-BARRIER-PEDS
Drugs: Baricitinib, LY3009104
Age
2 - 18 years
Phase
III
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-O...
Enrolling
Conditions: Crohn's Disease
Trial Name
SHINE-On
Drugs: Mirikizumab
Age
2 - 19 years
Phase
III
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)
Enrolling
Conditions: Juvenile Idiopathic Arthritis
Trial Name
JUVE-X
Drugs: Baricitinib
Age
1 year - 18 years
Phase
III
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-1
Drugs: Lebrikizumab, Topical corticosteroid
Age
6 months - 17 years
Phase
III
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)
Enrolling
Conditions: Ulcerative Colitis
Trial Name
SHINE-2
Drugs: LY3074828
Age
2 - 17 years
Phase
III
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Enrolling
Conditions: Obesity
Drugs: Tirzepatide
Age
12 - 17 years
Phase
III
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)
Enrolling
Conditions: Crohn's Disease
Trial Name
AMAY
Drugs: Mirikizumab
Age
2 - 17 years
Phase
III
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Derm...
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADmirable
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-...
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-2
Drugs: Lebrikizumab
Age
6 months - 18 years
Phase
III
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
Enrolling
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA-PEDS
Drugs: baricitinib
Age
6 - 17 years
Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
1 
Completed Enrollment
17  Total Trials
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors...
Completed Enrollment
Conditions: Advanced Solid Tumors
Drugs: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab and GM-CSF
Age
≤21 years
Phase
II